Vanda Pharmaceuticals Announces US Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Vanda Pharmaceuticals Announces US Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Consumers can now order NEREUS instantly at nereus.us WASHINGTON, May 1, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) at present introduced that NEREUS (tradipitant) is now commercially obtainable throughout the United States for the prevention of vomiting induced by movement in adults, marking the first new prescription drugs authorised for this situation in…

Read More